Lota S. Zoth
CIK 1278219 · CHIEF SCIENTIFIC OFFICER · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MEDI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BUFFALO GAP, TX 79508
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ENGNW | Director | — | $0.23 | — | $0 | 4 | 2026-06-17 |
| INO | Director | 8,726 | $0.87 | $7.6K | -$37.8K | 15 | 2026-05-21 |
| FFIN | Director | 2,142 | $30.00 | $64.3K | $0 | 1 | 2026-05-05 |
| 89bio, Inc. (ETNB) Delisted | Director | — | $14.84 | — | $0 | 7 | 2025-10-30 |
| LUMOS PHARMA, INC. (LUMO) Delisted | Director | 0 | $4.34 | $0 | $0 | 6 | 2024-12-13 |
| ZYME | Director | — | $28.37 | — | $0 | 4 | 2022-12-23 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | 1,112 | — | — | $0 | 11 | 2020-01-06 |
| Spark Therapeutics, Inc. (ONCE) Delisted | CHIEF SCIENTIFIC OFFICER | 0 | — | — | $0 | 6 | 2019-12-17 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2017-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 2 | 2015-05-08 |
| MEDI | SVP, Chief Financial Officer | 178 | $33.70 | $6.0K | -$46.2K | 3 | 2007-06-19 |
Recent Filings · Page 5 of 7
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-05-09 | INO | Grant (A) | — | $0 | EDGAR |
| 2019-05-08 | ZYME | Grant (A) | — | $0 | EDGAR |
| 2019-01-04 | INO | Grant (A) | — | $0 | EDGAR |
| 2018-05-31 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | +1,500 | $0 | EDGAR |
| 2018-05-25 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-18 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-02 | Spark Therapeutics, Inc. (ONCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-16 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-11 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-14 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.